| Literature DB >> 33823832 |
Sarah Elshahat1, Charlene Treanor2, Michael Donnelly2.
Abstract
BACKGROUND: It has been posited that physical activity (PA) has the potential to improve health outcomes and the health-related quality of life of people living with or beyond cancer. Despite the well-documented health benefits of PA, there is a low level of PA among cancer patients. A systematic scoping review was conducted to investigate attitudes, perceptions, preferences and barriers vs. facilitators to cancer patients' PA participation.Entities:
Keywords: Barriers; Cancer; Exercise; Facilitators; Health belief model; Physical activity
Mesh:
Year: 2021 PMID: 33823832 PMCID: PMC8025326 DOI: 10.1186/s12966-021-01116-9
Source DB: PubMed Journal: Int J Behav Nutr Phys Act ISSN: 1479-5868 Impact factor: 6.457
Fig. 1Flow diagram of the eligible studies
Fig. 2HBM-based conceptual model showing what predicts PA performance as a healthy behavior by cancer patients
Perceived benefits and risks of PA (% patients citing the benefit/risk)
| Cancer type | Country, no. of participants, treatment stage | Study design | Perceived benefits | Perceived risks | Reference | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physiological benefits | Psychosocial benefits | (A) Fatigue, (B) Pain, & (C) Risk of injury | ||||||||||||||||
| (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (A) | (B) | (C) | ||||
| Breast | Canada, 9, post-ttt | QI | + | + | + | + | + | [ | ||||||||||
| Canada, 8, during ttt | QI | + | + | + | + | + | [ | |||||||||||
| Canada, 12, mixed | FG | + | + (25) | + (8) | + (17) | + | + (17) | + | + | + (17) | + | [ | ||||||
| Canada, 12, post-ttt | QI | + | + | + | + | + | + | + | [ | |||||||||
| NZ, 20 women | FG | + | + | [ | ||||||||||||||
| Norway, 27 women, during ttt | FG | + | + | + | + | + | + | [ | ||||||||||
| Sweden, 16, on ttt | QI | + | + | + | + | + | + | + | + | [ | ||||||||
| US, 60 women | QI | + (28) | + (15) | + (5) | + (18) | [ | ||||||||||||
| US, 23 women, during ttt | CS | + (91) | + (91) | + (78) | + (91) | + (87) | + (83) | + (52) | + (78) | + (30) | + (4) | [ | ||||||
| Colo-rectal | Australia,10, post-ttt | QI | + | + | + | + | + | + | + | [ | ||||||||
| Canada, 600, post-ttt | CS | + (70) | + (66) | + (61) | + (58) | + (41) | + (52) | + (54) | + (44) | [ | ||||||||
| Canada, 30, mixed | QI | + (75) | + (56) | + (63) | + (50) | + (50) | + (24) | + (31) | + (50) | + (65) | [ | |||||||
| Sweden, 17 patients | QI | + | [ | |||||||||||||||
| Endom-etrial | UK, 16 women, post-ttt | QI | + | + | + | + | [ | |||||||||||
| Kidney | Canada, 482, post-ttt | CS | + (26) | + (25) | + (22) | + (23) | + (49) | + (3) | + (24) | [ | ||||||||
| Leuke-mia | US, 6, post-ttt | QI | + | + | + | + | + | + | [ | |||||||||
| Lung | Australia, 7, post-ttt | FG | + | + | + | + | + | [ | ||||||||||
| Denmark, 19, post-ttt | QI | + | + | + | + | + | + | [ | ||||||||||
| US, 43, pre-ttt | CS | + (13) | + (67) | + (18) | + (13) | + (48) | + (29) | +(14) | [ | |||||||||
| Multiple myeloma | Australia, 24 patients, post-ttt | QI | + | + | + | + | + | + | [ | |||||||||
| Ovarian | Australia, 12, mixed | QI | + | + | [ | |||||||||||||
| Prostate | Australia, 18, post-ttt | QI | + | + | + | + | + | + | + | [ | ||||||||
| Ireland, 20 men | QI | + | + | + | + | + | [ | |||||||||||
| Variousa | Australia, 9, on ttt | QI/FG | + | + | + | + | [ | |||||||||||
| Australia, 15, mixed | QI | + | + | + | + | + | + | + | + | [ | ||||||||
| Australia, 102, post-ttt | CS | + (88) | + (96) | + (44) | + (63) | + (68) | + (61) | [ | ||||||||||
| Canada, 788 patients | CS | + (76) | + (90) | [ | ||||||||||||||
| Canada, 66, mixed | CS | + | + | + | + | + | + | [ | ||||||||||
| Canada, 13, post-ttt | QI | + | + | + | + | + | + | + | + | [ | ||||||||
| England, 59, mixed | CS | + (40) | + (40) | + (10) | + (16) | + (10) | [ | |||||||||||
| Germany, 905 patients | CS | + (58) | + (68) | + (61) | [ | |||||||||||||
| Ireland, 41, mixed | FG | + | + | + | + | + | + | + | + | + | [ | |||||||
| Italy, 12 females, post-ttt | FG | + | + | [ | ||||||||||||||
| Netherlands, 13, post-ttt | QI | + | + | + | + | + | + | + | + | [ | ||||||||
| Norway, 7, on ttt | QI | + | + | + | + | + | [ | |||||||||||
| NZ, 25, mixed stages | QI | + | + | + | + | + | [ | |||||||||||
| Sweden, 18, during ttt | FG | + | + | + | + | + | + | + | + | + | + | [ | ||||||
| UK, 6, post-ttt | QI | + | + | + | + | + | + | + | + | + | [ | |||||||
| UK, 19, post-ttt | QI | + | + | + | + | [ | ||||||||||||
| UK, 16, mixed | QI | + | + | + | + | [ | ||||||||||||
| UK, 26, mixed | FG | + | + | + | + | + | + | + | + | [ | ||||||||
| UK, 456 patients | CS | + (87) | + (54) | [ | ||||||||||||||
| US, 20, during ttt | QI | + | + | + | + | + | + | [ | ||||||||||
| US, 25, post-ttt | FG | + | + | [ | ||||||||||||||
Abbreviations: CS cross-sectional, FG focus groups, MM mixed-method, NZ New Zealand, PA physical activity, QI qualitative interview, ttt treatment. a The study included various mixed cancer types
Preferences for PA types and places for practice (% patients reporting the preference)
| Cancer type | Country, no. of participants, treatment stage | Study design | PA types | Places for PA practice | Reference | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (A) Walking, (B) Cycling, (C) Swimming, (D) Jogging, (E) Dancing, (F) Gardening, (G) Gymnastics, (H) Strength training, (I) Ball sports, (J) Yoga, (K) Resistance weight training, and (L) Stretching | (A) Home, (B) Outdoors/park, (C) Fitness center, and (D) Cancer center/hospital | ||||||||||||||||||
| (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (A) | (B) | (C) | (D) | ||||
| Brain | Canada, 31, on ttt | CS | + (45) | + (6) | + (58) | + (16) | [ | ||||||||||||
| US, 106, mixed | CS | + (51) | + (44) | + (26) | + (9) | + (6) | [ | ||||||||||||
| Breast | Canada, 524, post-ttt | CS | + (51) | + (27) | + (36) | + (36) | + (32) | + (51) | + (5) | [ | |||||||||
| Canada, 12, mixed | FG | + | + | + | + | [ | |||||||||||||
| US, 60, post-ttt | QI | + (52) | + (37) | + (23) | + (80) | + (52) | [ | ||||||||||||
| US, 23, during ttt | CS | +(100) | + (74) | + (61) | + (4) | + (35) | + (52) | + (48) | + (30) | + (22) | [ | ||||||||
| US, 160, during ttt | CS | + (59) | + (23) | + (6) | + (14) | + (14) | + (22) | [ | |||||||||||
| Colo-rectal | Australia,10, post-ttt | QI | + | + | + | + | + | + | [ | ||||||||||
| Canada, 600, mixed | CS | + (49) | + (4) | + (8) | + (56) | + (40) | + (28) | + (10) | [ | ||||||||||
Netherlands, 15, mixed | QI | + | + | + | + | + | [ | ||||||||||||
| Endometrial | UK, 16, post-ttt | QI | + | [ | |||||||||||||||
| Gynecologic | Canada, 239 patients | MM | + (81) | [ | |||||||||||||||
| Lung | Australia, 7, post-ttt | FG | + | + | + | + | + | [ | |||||||||||
| US, 43, pre-ttt | CS | + (49) | + (14) | +(23) | [ | ||||||||||||||
| US, 175, post-ttt | CS | + (26) | + (6) | + (12) | + (6) | + (18) | +(10) | [ | |||||||||||
| Multiple myeloma | Australia, 24, post-ttt | QI | + | + | + | + | + | + | + | + | [ | ||||||||
| Ovarian | Canada, 359, mixed | CS | + (63) | + (3) | + (4) | + (4) | + (49) | + (21) | + (7) | [ | |||||||||
| Prostate | Australia, 18, post-ttt | QI | + | + | + | + | + | + | [ | ||||||||||
| Testicular | Norway, 9, mixed | QI | + (67) | + (11) | [ | ||||||||||||||
| Variousa | Australia, 92, during ttt | CS | + (68) | + (4) | + (6) | + (5) | + (9) | + (53) | + (15) | [ | |||||||||
| Canada, 66, mixed | CS | + (60) | +(32) | [ | |||||||||||||||
| England, 59, mixed | CS | + (52) | + (18) | +(73) | + (18) | + (17) | [ | ||||||||||||
| Germany, 155, mixed | CS | + (45) | + (45) | + (45) | + (13) | + (20) | + (13) | [ | |||||||||||
| Ireland, 41, mixed | FG | + (15) | + (66) | + (3) | + (68) | [ | |||||||||||||
| Italy, 392, mixed | CS | + (21) | + (27) | + (12) | [ | ||||||||||||||
| UK, 26, mixed stages | FG | + | [ | ||||||||||||||||
| UK, 456 patients | CS | + (73) | + (31) | + (34) | + (26) | + (31) | + (14) | + (23) | +(16) | [ | |||||||||
| US, 20, during ttt | QI | + (80) | [ | ||||||||||||||||
| US, 162, mixed | CS | + (73) | + (64) | + (58) | + (36) | + (35) | + (31) | + (91) | + (58) | + (64) | [ | ||||||||
Abbreviations: CS cross-sectional, FG focus groups, MM mixed-method, PA physical activity, QI qualitative interview, ttt treatment. a The study included various mixed cancer types
Preferences for PA information, timing and people to practice with (% patients reporting the preference)
| Cancer type | Country, no. of participants, treatment stage | Study design | Persons to provide information | Time to start PA program | People to perform PA with | Time of the day | Reference | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (A) Oncologist, (B) Family doctor, (C) Nurse, (D) Physiotherapist, & (E) Personal trainer | (A) At diagnosis, (B) During ttt, (C) Immediately after ttt, & (D) 3–6 months after ttt | (A) Alone, (B) Family/friends, & (C) Other cancer patients | (A) Morning, (B) Afternoon, & (C) Evening | |||||||||||||||
| (A) | (B) | (C) | (D) | (E) | (A) | (B) | (C) | (D) | (A) | (B) | (C) | (A) | (B) | (C) | ||||
| Brain | Canada, 31, during ttt | CS | + (52) | + (26) | + (7) | + (16) | + (29) | + (7) | [ | |||||||||
| US, 106, mixed | CS | + (24) | + (5) | [ | ||||||||||||||
| Breast | Canada, 12, post-ttt | QI | + | [ | ||||||||||||||
| Canada, 524, post-ttt | CS | + (14) | + (17) | + (14) | + (35) | + (21) | + (14) | + (37) | + (18) | + (50) | + (21) | + (14) | + (21) | + (17) | + (13) | [ | ||
| NZ, 20 patients | FG | + | [ | |||||||||||||||
| US, 23, during ttt | CS | + (39) | + (13) | + (30) | + (13) | + (35) | + (26) | +(39) | + (44) | + (30) | + (9) | [ | ||||||
| Colo-rectal | Australia,10, post-ttt | QI | + | + | + | + | [ | |||||||||||
| Canada, 600, mixed | CS | + (35) | + (12) | + (25) | + (18) | + (19) | + (9) | + (22) | + (28) | + (24) | + (22) | + (12) | [ | |||||
| Netherlands, 15, mixed | QI | + | + | + (53) | [ | |||||||||||||
| Endometrial | UK, 16 women, post-ttt | QI | + | [ | ||||||||||||||
| Gynecologic | Canada, 239 women | MM | + (63) | + (79) | [ | |||||||||||||
| Lung | Australia, 7, post-ttt | FG | + | + | + | [ | ||||||||||||
| US, 43, pre-ttt | CS | + (23) | + (19) | + (2) | + (12) | + (7) | + (16) | + (47) | + (21) | + (7) | + (23) | + (40) | + (7) | [ | ||||
| US, 175, post-ttt | CS | + (58) | + (8) | + (36) | + (9) | + (8) | + (13) | + (3) | [ | |||||||||
| Ovarian | Canada, 359, mixed | CS | + (18) | + (13) | + (26) | + (26) | + (49) | + (15) | + (17) | + (29) | + (31) | + (16) | [ | |||||
| Variousa | Australia, 92, during ttt | CS | + (18) | + (17) | + (9) | + (41) | + (21) | + (35) | [ | |||||||||
| Ireland, 41, mixed | FG | + | + | + | + | [ | ||||||||||||
| Italy, 392, mixed | CS | + (57) | + (7) | + (30) | + (20) | + (48) | + (31) | + (9) | + (16) | + (8) | + (27) | [ | ||||||
| Norway, 7, during ttt | QI | + | [ | |||||||||||||||
| UK, 12, mixed stages | QI | + | + | + | + | [ | ||||||||||||
| UK, 26, mixed stages | FG | + | + | + | + | + | [ | |||||||||||
| UK, 456, post-ttt | CS | + (17) | + (14) | + (11) | + (23) | + (7) | + (5) | + (25) | + (34) | + (20) | +(15) | + (15) | + (19) | + (38) | [ | |||
| US, 20, during ttt | QI | + (80) | [ | |||||||||||||||
Abbreviations: CS cross-sectional, FG focus groups, MM mixed-method, NZ New Zealand, PA physical activity, QI qualitative interview. ttt: treatment. aThe study included various mixed cancer types
Barriers to PA participation among cancer patients (% patients reporting the barrier)
| Cancer type | Country, no. of participants, treatment stage | Study design | Physiological | Psychosocial & | Economic & environmental | Reference | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (A) Treatment side effects, & (B) Co-morbidities | (A) Low self-efficacy & motivation, (B) Low exercise discipline, (C) Kinesiophobia & (D) Not sporty, (E) Lack of social support, (F) Family responsibility, (G) Preference for other activities, & (H) Time pressures | (A) Financial issues, (B) Poor weather, & (C)Unavailable/ inaccessible facilities | ||||||||||||||
| (A) | (B) | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (A) | (B) | (C) | ||||
| Breast | Canada, 9, post-ttt | QI | + | + | + | + | + | + | + | + | + | + | + | [ | ||
| Canada,160, during ttt | CS | + (41) | + (4) | + (11) | + (6) | [ | ||||||||||
| Canada, 8, during ttt | QI | + | + | + | + | + | + | + | [ | |||||||
| Canada, 12, mixed | QI | + | + | + | + | + | + | + | [ | |||||||
| Canada, 12, mixed | FG | + | + | + | + | + | + | + | + | + | [ | |||||
| NZ, 20 women | FG | + | + | + | + | + | [ | |||||||||
| Norway, 10, during ttt | QI | + | + | [ | ||||||||||||
| Norway, 27, during ttt | FG | + | + | + | + | [ | ||||||||||
| Spain, 14, post-ttt | QI | + | + | + | + | + | + | [ | ||||||||
| Sweden, 16, during ttt | QI | + | + | + | + | + | [ | |||||||||
| UK, 83, during ttt | QI | + | + | + | + | + | + (20) | + | + | + | + (48) | + | [ | |||
| US, 23, during ttt | CS | + (39) | + (39) | +(52) | + | + | + (26) | + (22) | + (26) | + (39) | + (22) | + | + (22) | [ | ||
| US, 30 women, on ttt | QI | + | + | + | [ | |||||||||||
| US, 60 elderly, post-ttt | QI | + (43) | + (22) | + (40) | [ | |||||||||||
| Colo-rectal | Canada, 600, post-ttt | CS | + (14) | + (9) | + (15) | + (16) | + (15) | + (25) | [ | |||||||
| Canada, 69 survivors | RCT | + (25) | + (1) | + (3) | + (32) | + (1) | [ | |||||||||
| Netherland, 15, mixed | QI | + | + | + | + | + | [ | |||||||||
| Spain, 30, during ttt | QI | + | + | + | + | + | + | [ | ||||||||
| Sweden, 17 elderly | QI | + | + | + | + | + | + | + | + | + | [ | |||||
| US, 30, mixed stages | QI | + | + | + | + | [ | ||||||||||
| Endometrial | UK, 16, post-ttt | QI | + | + | + | + | + | + | [ | |||||||
| Gynecologic | Canada, 239 patients | MM | + | + | + | + | [ | |||||||||
| Head/neck | England, 430, post-ttt | CS | + | + | + | + | + | + | + | + | + | + | + | + | + | [ |
| Kidney | Canada, 482, post-ttt | CS | + (20) | + (24) | + (14) | + (19) | + (22) | + (15) | + (8) | [ | ||||||
| Lung | Australia, 7, post-ttt | FG | + | + | + | + | + | + | + | + | + | + | + | [ | ||
| Denmark, 19, post-ttt | QI | + | + | [ | ||||||||||||
| France, 5, during ttt | QI | + | + | + | + | + | + | [ | ||||||||
| UK, 28 patients | MM | + | [ | |||||||||||||
| US, 43, pre-ttt | CS | + (34) | +(16) | [ | ||||||||||||
| Lung & GI | US, 34 patients | QI | + | + | + | + | + | + | + | + | + | + | [ | |||
| Lymphoma | US, post-ttt survivors | FG | + | + | [ | |||||||||||
| Multiple myeloma | Australia, 24, post-ttt | QI | + | + | + | [ | ||||||||||
| Ovarian | Australia, 95, mixed | CS | + (38) | + (26) | + (36) | + (12) | +(35) | + (11) | + (13) | + (21) | + (14) | + (7) | + (12) | + (6) | [ | |
| Australia, 95, mixed | CS | + (38) | + | + | + (33) | +(35) | + | [ | ||||||||
| US, 10 women, post-ttt | QI | + | + | + | + | + | + | [ | ||||||||
| Prostate | Australia, 18, post-ttt | QI | + | + | + | + | + | [ | ||||||||
| Australia, 14 men | QI | + | + | + | + | + | + | + | + | [ | ||||||
| England, 16 men, post-ttt | QI | + | + | + | + | + | + | [ | ||||||||
| Ireland, 20 men | QI | + | + | + | + | + | + | [ | ||||||||
| Sarcoma | UK, 6, during ttt | QI | + | + | + | [ | ||||||||||
| Variousa | Australia, 101, mixed | CS | + | + | + | [ | ||||||||||
| Australia, 20, on ttt | QI | + | + | + | + | [ | ||||||||||
| Australia, 10, post-ttt | CS | + (52) | + (14) | + (9) | + (5) | + (39) | + (34) | + (15) | + (13) | [ | ||||||
| Australia, 92, during ttt | CS | + (51) | + | [ | ||||||||||||
| Australia, 15, mixed | QI | + | + | + | + | + | + | [ | ||||||||
| Australia, 9, during ttt | QI/FG | + | + | + | + | [ | ||||||||||
| Canada,66, mixed stages | CS | + | + | + | + | + | [ | |||||||||
| Canada, 788 patients | CS | + (41) | + (4) | + (30) | + (13) | + (14) | + (25) | + (19) | + (30) | + (26) | + (10) | [ | ||||
| Canada, 30, during ttt | CS | + (74) | + (82) | + (26) | + (60) | [ | ||||||||||
| Denmark, 33, during ttt | QI | + | + | + | + | + | + | [ | ||||||||
| Denmark, 451, during ttt | CS | + (74) | + (14) | + (14) | + (13) | + (15) | [ | |||||||||
| England, 41, post-ttt | CS | + (32) | + (12) | + (12) | + (18) | + (27) | + (15) | [ | ||||||||
| England, 59, mixed | CS | + (48) | + (22) | + (18) | + (18) | + (18) | +(10) | + (45) | + (20) | [ | ||||||
| Germany, 141 patients | CS | + (77) | + (85) | + (50) | + (27) | +(40) | + | + (5) | + (5) | + (4) | + (7) | [ | ||||
| Ireland, 41, mixed | FG | + | + | + | + | + | + | + | + | [ | ||||||
| Italy, 12 females, post-ttt | FG | + | + | + | + | + | + | [ | ||||||||
| NZ, 25, mixed stages | QI | + | + | + | + | + | + | [ | ||||||||
| Norway, 7, during ttt | QI | + | [ | |||||||||||||
| Sweden, 18, during ttt | FG | + | + | + | + | + | + | [ | ||||||||
| UK, 19, post-ttt | QI | + | + | + | + | + | [ | |||||||||
| UK, 456, post-ttt | CS | + (36) | + (37) | + (27) | + (20) | + (26) | + (26) | [ | ||||||||
| UK, 6, post-ttt | QI | + | + | + | + | + | + | + | [ | |||||||
| UK, 12, mixed stages | QI | + | + | + | [ | |||||||||||
| UK, 1, mixed stages | QI | + | + | + | + | [ | ||||||||||
| UK, 26, mixed stages | FG | + | + | + | + | + | + | + | [ | |||||||
| US, 25, post-ttt | FG | + | + | + | + | + | + | [ | ||||||||
| US, 162, mixed stages | CS | + (34) | + (36) | + (24) | + (35) | + (24) | [ | |||||||||
| US, 662, mixed stages | CS | + (78) | + (67) | + (24) | + (6) | + (29) | + (20) | + (11) | [ | |||||||
| US, 20, post-ttt | QI | + | + | + | + | + | + | + | [ | |||||||
| US, 20, during ttt | QI | + | + | [ | ||||||||||||
| US, 452 patients | CS | + | + | + | + | + | + | + | + | + | [ | |||||
| US, 622 patients | CS | + (78) | + (68) | + (65) | [ | |||||||||||
| US, 590 patients | CS | + | + | + (8) | + (21) | [ | ||||||||||
| US, 566 older adults | CS | + | [ | |||||||||||||
| US, 640 patients | CS | + (27) | + (3) | + (11) | + (27) | + (3) | [ | |||||||||
| US, 13, mixed stages | QI | + | + | + | + | + | [ | |||||||||
Abbreviations: CS cross-sectional, FG focus groups, MM mixed-method, NZ New Zealand, PA physical activity, QI qualitative interview, ttt treatment, RCT randomized controlled trial. a The study included various mixed cancer types
Facilitators to PA participation among cancer patients (% patients reporting the facilitator)
| Cancer type | Country, no. of participants, treatment stage | Study design | Physiological | Psychosocial & cultural | Economic & environmental | Reference | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (A) Feeling well, & (B) Symptom management strategies | (A) Positive previous experience, (B) Perceived benefits, (C) Exercise in routine | (A) Affordable programs, & (B) Accessible/ tailored amenities | ||||||||||
| (A) | (B) | (A) | (B) | (C) | (D) | (E) | (A) | (B) | ||||
| Breast | Canada, 9 women, post-ttt | QI | + | + | + | + | + | + | [ | |||
| Canada, 8, during ttt | QI | + | + | + | + | + | + | [ | ||||
| Canada, 12, mixed stages | QI | + | + | [ | ||||||||
| New Zealand, 20 women | FG | + | + | + | [ | |||||||
| Norway, 27, during ttt | FG | + | + | + | [ | |||||||
| Spain, 14 women, post-ttt | QI | + | + | + | + | [ | ||||||
| Sweden, 16, during ttt | QI | + | + | + | [ | |||||||
| Sweden, 29, post-ttt | MM | + | + | + | [ | |||||||
| Sweden, 12, post-ttt | QI | + | [ | |||||||||
| US, 15 women, post ttt | QI | + | + | + | [ | |||||||
| US, 60 women, post-ttt | QI | + (50) | + (97) | + (20) | [ | |||||||
| US, 30 women, during ttt | QI | + | + | [ | ||||||||
| Colo-rectal | Canada, 600, post-ttt | CS | + (10) | + (13) | + (12) | [ | ||||||
| Netherlands, 15, mixed | QI | + | + | + | + | + | + | + | [ | |||
| Sweden, 17 patients | QI | + | + | + | + | + | [ | |||||
| Endometrial | UK, 16 women, post-ttt | QI | + | + | + | [ | ||||||
| Gynecologic | Canada, 239 survivors | MM | + (50) | + (50) | + | + | + | [ | ||||
| Kidney | Canada, 482, post-ttt | CS | + (47) | + (7), | [ | |||||||
| Lung | Australia, 7, post-ttt | FG | + | + | + | + | [ | |||||
| Denmark, 19, post-ttt | QI | + | + | + | + | [ | ||||||
| France, 5 patients | QI | + | + | + | [ | |||||||
| US, 43, during ttt | CS | + (15) | + (11) | + (15) | + (37) | [ | ||||||
| Lung & GI | US, 34 patients | QI | + | + | + | + | + | [ | ||||
| Lymphoma | US, N/A, post-ttt | FG | + | + | [ | |||||||
| Prostate | Australia, 18 men, post-ttt | QI | + | + | [ | |||||||
| Australia, 14 men | QI | + | + | + | [ | |||||||
| England, 16 men, post-ttt | QI | + | + | + | + | + | [ | |||||
| Ireland, 20 men | QI | + | [ | |||||||||
| Variousa | Australia, 15, mixed stages | QI | + | + | + | [ | ||||||
| Australia, 9, during ttt | QI/FG | + | + | + | + | [ | ||||||
| Australia, 102, post-ttt | CS | + | + (99) | + (97) | + (81) | + | [ | |||||
| Australia, 20, during ttt | QI | + | + | [ | ||||||||
| Canada, 30, during ttt | CS | + (63) | + (37) | + | + (32) | + | + (42) | [ | ||||
| Denmark, 33, during ttt | QI | + | + | + | + | + | [ | |||||
| Germany, 905 patients | CS | + | + | + | [ | |||||||
| Ireland, 41, mixed stages | FG | + | + | + | [ | |||||||
| Italy, 12, post-ttt | FG | + | + | + | + | + | + | [ | ||||
| New Zealand, 25, mixed | QI | + | + | + | [ | |||||||
| Sweden, 18, during ttt | FG | + | + | + | + | + | [ | |||||
| UK, 26, mixed stages | FG | + | + | + | + | + | [ | |||||
| UK, 456, post-ttt | CS | + | + | + | + | [ | ||||||
| UK, 19 patients, post-ttt | QI | + | + | + | [ | |||||||
| UK, 12, mixed stages | QI | + | + | + | [ | |||||||
| UK, 16, mixed stages | QI | + | + | [ | ||||||||
| US, 25, post-ttt | FG | + | + | + | + | + | [ | |||||
| US, 20, post-ttt | QI | + | + | + | + | [ | ||||||
| US, 13, mixed stages | QI | + | + | + | [ | |||||||
Abbreviations: CS cross-sectional, FG focus groups, MM mixed-method, N/A non-available, PA physical activity, QI qualitative interview, ttt treatment. a The study included various mixed cancer types